Myriad Genetics Unveils Key Findings from RiskScore Study
Myriad Genetics, Inc. (NASDAQ: MYGN), a pioneer in molecular diagnostics and precision medicine, has recently made headlines with the publication of a groundbreaking study in JCO Precision Oncology. This study brings forth new insights into how the RiskScore tool influences breast cancer screening decisions among clinicians based on individual patient risk factors.
Understanding the Impact of RiskScore
The study, titled "Association of Polygenic-based Breast Cancer Risk Prediction with Patient Management," showcases the effectiveness of RiskScore, which is part of the MyRisk Hereditary Cancer Test. This innovative assessment combines a polygenic risk score (PRS) that applies across diverse ancestries and is integrated with the established Tyrer-Cuzick model. Together, these tools help predict both the five-year and lifetime risk of developing breast cancer.
Key Outcomes of the Study
The research reveals several significant outcomes:
Disparities in Risk Level Predictions
Notably, RiskScore predicted a different risk level than the Tyrer-Cuzick model for nearly 20% of patients evaluated. This discrepancy underscores the importance of utilizing multiple assessment tools to adequately gauge patient risk and inform recommendations.
Influenced Screening Practices
The study found that patients identified with a lifetime risk of breast cancer at or above 20%, indicated by RiskScore predictions, were significantly more likely to participate in guideline-recommended screenings such as mammography, breast MRI, and even genetic counseling. This highlights how tailored risk predictions can ensure patients receive appropriate medical attention based on their specific profiles.
Perspectives from Leading Experts
Allison Kurian, MD, MSc, a distinguished professor at Stanford University and senior author of the study, remarked on the relatively recent introduction of polygenic risk predictors. Kurian emphasized the reassurance provided by the study, indicating that patients were indeed receiving adequate breast cancer screenings post-RiskScore testing. Furthermore, she stated that this study illustrates how clinicians are increasingly integrating RiskScore results into their screening recommendations.
A Step Forward in Personalized Medicine
Another key contributor to the study, Katie Johansen Taber, PhD, who serves as VP of Clinical Product Research & Partnerships at Myriad, expressed that this landmark study is instrumental in understanding the medical management of patients based on their individual risk. She noted that with tools like MyRisk that incorporates RiskScore, patients can better understand their genetic predispositions to breast cancer, empowering both clinicians and patients to collaborate effectively on managing this risk.
About the Study Methodology
The methodology of the study involved analyzing de-identified RiskScore results in correlation with insurance claims data to assess the type and frequency of breast cancer screenings undertaken in the year following genetic testing. The findings revealed a clear trend: patients who received RiskScore assessments indicating a 20% or greater lifetime risk of breast cancer tended to pursue more rigorous screening protocols, while those classified below this threshold did not demonstrate the same level of proactive screening.
About MyRisk and Its Role in Cancer Prevention
The MyRisk Hereditary Cancer Test with RiskScore assesses 48 genes tied to hereditary cancer risk. By evaluating genetic abnormalities, it offers a tailored analysis of each patient's risk across 11 different types of cancer. Coupled with family history and other risk factors, it produces a comprehensive five-year and lifetime breast cancer risk estimate that is unique to each patient, fostering personalized care.
Why Myriad Genetics Matters
As a leader in molecular diagnostics and precision medicine, Myriad Genetics is committed to improving health outcomes through cutting-edge testing solutions. The company's suite of molecular tests provides crucial risk assessments and treatment guidance, paving the way for enhanced patient care and reduced healthcare expenses across various medical fields. For more details about Myriad's initiatives, visit their website at www.myriad.com.
Frequently Asked Questions
What is the main focus of the RiskScore study?
The study aims to evaluate how the RiskScore assessment tool affects breast cancer screening recommendations for patients based on their genetic risk levels.
How does RiskScore differ from older methods?
RiskScore uses a polygenic risk score along with the Tyrer-Cuzick model, offering a more comprehensive risk prediction that considers genetic and ancestral factors.
What were the significant findings related to patient screening?
Patients with a 20% or greater lifetime risk of breast cancer were found to undergo more screening procedures that align with established guidelines compared to those with lower risk predictions.
Who are the key researchers involved in this study?
The study features contributions from Allison Kurian, MD, MSc, and Katie Johansen Taber, PhD, both of whom emphasize the implications of personalized genetic insights in enhancing patient management.
What is the significance of MyRisk in cancer prevention?
MyRisk provides a detailed hereditary cancer risk assessment, enabling patients and healthcare providers to make informed decisions regarding preventive care based on individual genetic profiles.
